Clinical Trials Logo
  1. Home
  2. Thyroid Carcinoma
  3. NCT04327999

Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System

Thyroid Carcinoma Clinical Trial

Official title:
Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System of Patients Following Radioiodine Therapy for Thyroid Carcinoma

Clinical Trial Summary

The purpose of this study is to explore whether administration of preservative free artificial tears will decrease the level of detectable radioiodine in the tears and nasolacrimal duct system of patients undergoing radioiodine therapy for thyroid carcinoma and thus decrease the risk of developing radioactive iodine associated nasolacrimal duct obstruction.

Clinical Trial Description

Primary Objective: - To assess whether use of preservative free artificial tears following radioactive iodine administration will lower the level of radioactive iodine in the tears of patients treated with radioactive iodine for thyroid carcinoma. Secondary Objective: - To evaluate whether artificial tears would be an effective preventative intervention to decrease the risk of developing nasolacrimal duct stenosis, which has been associated with radioactive iodine administration. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04327999
Study type Interventional
Source Vanderbilt-Ingram Cancer Center
Contact
Status Terminated
Phase Phase 2
Start date October 5, 2020
Completion date September 25, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT02658513 - Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
Withdrawn NCT01707056 - The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma N/A
Completed NCT00215605 - Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies Phase 1
Completed NCT02194920 - Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function N/A
Enrolling by invitation NCT06095362 - Thyroid Cancer and Central Lymph Node Metastases Detection Using Bevacizumab-IRDye800CW Phase 1
Not yet recruiting NCT05949424 - OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults Phase 4
Active, not recruiting NCT02145143 - Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study N/A
Terminated NCT01865838 - A Study Into the Effect of Seprafilm in Open Total Thyroidectomy N/A
Recruiting NCT00749697 - Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases N/A
Enrolling by invitation NCT04411290 - Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases
Completed NCT01813136 - Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma Phase 2
Recruiting NCT05668962 - Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC Phase 2
Active, not recruiting NCT02185560 - Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
Completed NCT04462471 - Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers Phase 1
Completed NCT01433809 - Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm N/A
Recruiting NCT00929318 - Influence of Thyroid Hormones on the Woundhealing Process N/A
Completed NCT05178186 - Impact of the COVID-19 Pandemic on Surgery for Thyroid Cancer N/A
Completed NCT02773667 - Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine
Not yet recruiting NCT00993837 - Feasibility of Endoscopic Thyroidectomy for Thyroid Carcinoma N/A
Completed NCT01013597 - Trial of LBH589 in Metastatic Thyroid Cancer Phase 2